Indications
Vgenfli is indicated for adults for the treatment of- neovascular (wet) age-related macular degeneration (AMD),- visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO),- visual impairment due to diabetic macular oedema (DME),- visual impairment due to myopic choroidal neovascularisation (myopic CNV).
Composition
- Active substance
- aflibercept
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Vgenfli
- Active substance
- aflibercept
- ATC code
- S01LA05
- Group
- Sensory organs
- Therapeutic area
- Wet Macular Degeneration, Macular Edema, Diabetes Complications, Retinal Vein Occlusion, Choroidal Neovascularization